Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
BillionToOne Q1 2026 Earnings Call - Profitable Growth Accelerates with Unity Confirm Launch and Anthem Contract
BillionToOne delivered a quarter of compounding growth and rare profitability for a high-growth molecular diagnostics company. Revenue surged 84% year-over-year to $108.4 million, driven by a 44% incr...
- Revenue grew 84% year-over-year to $108.4 million, with test volumes up 44% and ASPs rising 28% to $571 per test.
- GAAP operating margin reached 16% and adjusted EBITDA margin hit 24%, marking the third consecutive quarter of Rule of 100+ performance paired with profitability.
- Gross margins expanded 9 percentage points year-over-year to 73%, driven by prenatal ASP growth and COGS reductions in oncology.
- +7 more takeaways
"Chegg, Inc." Q1 2026 Earnings Call - AI-Driven Skilling Growth and Balance Sheet Strength
Chegg delivered a strong Q1 2026, surpassing revenue, profitability, and free cash flow expectations while aggressively reducing debt. The company's strategic pivot to an AI-first model is yielding ta...
- Chegg exceeded Q1 2026 expectations across revenue, profitability, and free cash flow, signaling a successful turnaround under renewed leadership.
- Chegg Skilling revenue reached $17.6 million, up 9% year-over-year, with management targeting double-digit full-year growth driven by new enterprise and channel partnerships.
- The company has re-architected its product and cost base around AI, enabling faster content creation, real-time learning interventions, and a 55% year-over-year reduction in non-GAAP operating expenses.
- +7 more takeaways
Savers Value Village Q1 2026 Earnings Call - Thrift Adoption Accelerates in U.S. While Canada Optimizes for Margin
Savers Value Village delivered a strong start to 2026 with U.S. comp sales jumping 6.4%, fueled by broad-based demand across income cohorts and a powerful secular shift toward secondhand shopping. The...
- U.S. comp sales grew 6.4%, driven by gains in both average basket size and transaction counts, signaling broad-based consumer adoption across income demographics.
- Canadian comp sales declined 0.6%, primarily due to a 70 basis point headwind from an early Easter, but macro conditions remain sluggish in key markets like Southern Ontario.
- Canadian segment profit surged 24% year-over-year, expanding margins by 310 basis points through tight production management and offsite efficiency initiatives.
- +9 more takeaways
LifeMD Q1 2026 Earnings Call - Record Subscriber Growth and Strategic Pivot to Branded GLP-1s and Insurance-Backed Care
LifeMD reported a strong first quarter of 2026, delivering $50.2 million in revenue and adding 42,000 net telehealth subscribers, marking the largest quarterly net addition in the company's history. T...
- LifeMD delivered Q1 2026 revenue of $50.2 million, exceeding guidance and marking a strong start to the year despite flat year-over-year growth due to a product mix shift.
- The company added 42,000 net telehealth subscribers in Q1, the largest quarterly net addition in its history, ending the quarter with over 365,000 active subscribers.
- Weight management sign-ups surged approximately 120% sequentially, driven by the launch of oral GLP-1 therapies and improved customer acquisition economics.
- +7 more takeaways
Sight Sciences Q1 2026 Earnings Call - Dry Eye Revenue Nearly Doubles as Glaucoma Growth Accelerates
Sight Sciences delivered a strong start to 2026, driven by a near-doubling of its interventional dry eye revenue and a third consecutive quarter of growth in its interventional glaucoma segment. The c...
- Interventional dry eye revenue nearly doubled to $1.4 million in Q1 2026, up from $0.4 million in Q4 2025, validating the reimbursed business model.
- Interventional glaucoma revenue grew 7% year-over-year to $18.3 million, marking the third consecutive quarter of YoY growth.
- Full-year 2026 revenue guidance raised to $83 million to $89 million, reflecting 7% to 15% growth compared to 2025.
- +7 more takeaways
Lantronix Q3 FY2026 Earnings Call - Drone Revenue Surges as Edge AI Compute Becomes Mission-Critical
Lantronix delivered Q3 FY2026 revenue of $30.2 million and non-GAAP EPS of $0.04, with embedded IoT solutions driving 22% year-over-year growth. The company is rapidly scaling its unmanned systems bus...
- 1. Q3 FY2026 revenue reached $30.2 million, with non-GAAP EPS of $0.04, both within guidance. Embedded IoT solutions grew 22% year-over-year, driving overall growth.
- 2. Fiscal 2026 drone revenue outlook raised to $10-14 million, with a midpoint of $12 million, up from minimal contributions just nine months ago. Management expects drone revenue to double in FY2027, representing 15-20% of total revenue.
- 3. Gross margin remained strong at approximately 43%, supported by a richer mix of higher-margin embedded compute products and recurring software/services revenue.
- +9 more takeaways
Red Violet Q1 2026 Earnings Call - Record Revenue and Margins Signal Path to 65% EBITDA
Red Violet delivered a record first quarter for 2026, posting $25.8 million in revenue and crossing the $100 million annual run rate for the first time. The company reported record adjusted gross prof...
- Red Violet reported record Q1 2026 revenue of $25.8 million, up 17% year-over-year, crossing the $100 million annual run rate threshold for the first time.
- Adjusted gross profit reached a record $22 million, driving an expanded adjusted gross margin of 85%, up two percentage points from the prior year.
- Adjusted EBITDA surged 27% to a record $10.7 million, with the margin expanding three percentage points to 41%, validating management's long-term margin framework.
- +9 more takeaways
LegalZoom Q1 2026 Earnings Call - AI-Driven Margin Expansion and Concierge Suite Acceleration
LegalZoom delivered a quarter of decisive execution, proving its subscription-led, AI-enabled strategy is no longer a narrative but a financial reality. Total revenue grew 13% to $207 million, with ad...
- Total revenue grew 13% year-over-year to $207 million, exceeding management expectations and reflecting strong momentum in both subscription and transactional segments.
- Subscription revenue increased 12% to $130 million, marking the fourth consecutive quarter of double-digit growth, driven by the shift toward higher-value human-in-the-loop offerings.
- The Concierge Suite is emerging as a critical growth lever, now generating over three times the average ARPU and serving as a strategic entry point for established small business customers.
- +7 more takeaways
RxSight Q1 2026 Earnings Call - LAL Volumes Stabilize, Management Reaffirms $120M-$135M Revenue Guidance Amidst Turnaround Efforts
RxSight reported Q1 2026 revenue of $30.9 million, an 18% year-over-year decline driven by a step-down in Light Delivery Device (LDD) unit volumes, though Light Adjustable Lens (LAL) procedure volumes...
- Q1 2026 revenue came in at $30.9 million, down 18% year-over-year, with LAL procedure volumes of 27,472 units remaining largely flat compared to the prior year period.
- LDD unit sales dropped to just 20 units, contributing approximately $2 million to quarterly sales, while the installed base of LDDs grew to 1,154 units.
- Gross margins improved to 76.1% in Q1 from 74.8% in the prior year period, driven by a higher revenue mix from LAL procedures despite management's warning of impending absorption pressures from higher-cost inventory.
- +7 more takeaways
Mirum Pharmaceuticals Q1 2026 Earnings Call - Raised 2026 Revenue Guidance to $660M-$680M on Strong LIVMARLI Uptake and Rare Disease Pipeline Expansion
Mirum Pharmaceuticals delivered a quarter defined by execution and strategic expansion, raising full-year revenue guidance to $660 million-$680 million on robust uptake of LIVMARLI, particularly in th...
- Mirum raised full-year 2026 revenue guidance to $660 million-$680 million, up from previous estimates, driven by strong LIVMARLI uptake in adult PFIC patients and better-than-expected international sales.
- First-quarter 2026 net product sales reached approximately $160 million, with LIVMARLI generating $84 million in the U.S. and $30 million internationally, while bile acid medicines contributed $46 million.
- The company is expanding its U.S. liver commercial team from 20 to approximately 60 personnel by early 2027 to cover adult prescribers for PSC, hepatitis delta, and broader rare liver diseases.
- +7 more takeaways